Text Size

Choroidal Thickness in Glaucoma Patients and Healthy Controls

This study is enrolling participants by invitation only.
Sponsor:
Information provided by (Responsible Party):
University of Zurich
ClinicalTrials.gov Identifier:
NCT01293474
First received: February 9, 2011
Last updated: November 3, 2011
Last verified: November 2011
History of Changes
  Purpose

With the new software tool (EDI, enhanced depth imaging) of the Spectralis® spectral-domain optical coherence tomography (SD-OCT) it is possible to visualize and measure the choroidal thickness. In glaucoma a vascular component is known. Therefore a difference of choroidal thickness in glaucoma patients and healthy controls is proposed.

  • Trial with medical device

Condition Intervention Phase
Glaucoma Patients and Healthy Controls
 Device: Spectralis® SD-OCT, Heidelberg Engineering GmbH, H
 Phase 4

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective

Resource links provided by NLM:

MedlinePlus related topics: Glaucoma
U.S. FDA Resources

Further study details as provided by University of Zurich:

Estimated Enrollment: 200
Study Start Date: February 2011
Estimated Study Completion Date: December 2012
Groups/Cohorts Assigned Interventions
glaucoma patients
patients with diagnosis of primary open angle glaucoma
 Device: Spectralis® SD-OCT, Heidelberg Engineering GmbH, H
Measurement of the choroidal thickness with Spectralis® SD-OCT
control group
age matched healthy controls
 Device: Spectralis® SD-OCT, Heidelberg Engineering GmbH, H
Measurement of the choroidal thickness with Spectralis® SD-OCT

  Eligibility

Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

patients and controls are selected out of our primary care clinic

Criteria

Inclusion criteria: for both groups (glaucoma study group and control group):

men and women of at least 50 years of age

for the glaucoma study group: diagnosis of primary open angle glaucoma (POAG)

Exclusion criteria: for both groups (glaucoma study group and control group):

  • less then 50 years of age
  • any pathology of the central retina
  • any optic nerve disorder other then glaucoma
  • retinal vascular disorder

for the glaucoma study group: other glaucoma diagnosis then primary open angle glaucoma

for the control group: any diagnosis of glaucoma

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01293474

Locations
Switzerland
University Hospital Zurich, Ophthalmic Clinic
Zurich, ZH, Switzerland, 8091
Sponsors and Collaborators
University of Zurich
Investigators
Principal Investigator: Christoph Kniestedt, Ass. Prof., MD University Hospital Zurich, Ophtalmic Clinic
  More Information

No publications provided

Responsible Party: University of Zurich
ClinicalTrials.gov Identifier: NCT01293474     History of Changes
Other Study ID Numbers: EDI-OCT
Study First Received: February 9, 2011
Last Updated: November 3, 2011
Health Authority: Switzerland: Swissmedic

Additional relevant MeSH terms:
Glaucoma
Ocular Hypertension
Eye Diseases

ClinicalTrials.gov processed this record on June 18, 2013